Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1 Flow chart distinguishing groups according to receipt of azithromycin treatment and method of data collection. Circles containing the abbreviation.

Published byClarence Owens Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 1 Flow chart distinguishing groups according to receipt of azithromycin treatment and method of data collection. Circles containing the abbreviation."— Presentation transcript:

1 Figure 1 Flow chart distinguishing groups according to receipt of azithromycin treatment and method of data collection. Circles containing the abbreviation “Az” indicate the time of mass administration of azithromycin to all children 1–10 years of age as part of an ongoing project described elsewhere [15]. Shaded swab symbol, time nasopharyngeal swab obtained, questionnaire administered, and skin examination performed. “Study period” refers to the present study to determine the secondary effects of mass administration of azithromycin From: Adverse and Beneficial Secondary Effects of Mass Treatment with Azithromycin to Eliminate Blindness Due to Trachoma in Nepal Clin Infect Dis. 2002;35(4): doi: /341414 Clin Infect Dis | © 2002 by the Infectious Diseases Society of America

2 Table 1 Demographic and clinical characteristics of children in 3 groups at baseline (day 0) in study of secondary effects of mass treatment with azithromycin From: Adverse and Beneficial Secondary Effects of Mass Treatment with Azithromycin to Eliminate Blindness Due to Trachoma in Nepal Clin Infect Dis. 2002;35(4): doi: /341414 Clin Infect Dis | © 2002 by the Infectious Diseases Society of America

3 Table 2 Rates of nasopharyngeal carriage and antimicrobial resistance for Streptococcus pneumoniae isolates from children in study of secondary effects of mass treatment with azithromycin From: Adverse and Beneficial Secondary Effects of Mass Treatment with Azithromycin to Eliminate Blindness Due to Trachoma in Nepal Clin Infect Dis. 2002;35(4): doi: /341414 Clin Infect Dis | © 2002 by the Infectious Diseases Society of America

4 Table 3 Proportions of children with impetigo (detected by skin examination) and symptoms of illness (reported during interview) on days 0 and 10 From: Adverse and Beneficial Secondary Effects of Mass Treatment with Azithromycin to Eliminate Blindness Due to Trachoma in Nepal Clin Infect Dis. 2002;35(4): doi: /341414 Clin Infect Dis | © 2002 by the Infectious Diseases Society of America

5 Figure 2 Comparison of proportions of children with symptoms of gastrointestinal illness (reported during interview) and impetigo (detected by skin examination) at days 0, 10, and 180 after administration of azithromycin. NA, not applicable because no nasopharyngeal swabs were obtained at day 10. *P <.05 for comparison with day 0 From: Adverse and Beneficial Secondary Effects of Mass Treatment with Azithromycin to Eliminate Blindness Due to Trachoma in Nepal Clin Infect Dis. 2002;35(4): doi: /341414 Clin Infect Dis | © 2002 by the Infectious Diseases Society of America

Download ppt "Figure 1 Flow chart distinguishing groups according to receipt of azithromycin treatment and method of data collection. Circles containing the abbreviation."

Similar presentations

Table 3 Clinical response success rate, according to prior effective antimicrobial therapy in hospitalized patients with community-acquired pneumonia given.

Table 3 Clinical response success rate, according to prior effective antimicrobial therapy in hospitalized patients with community-acquired pneumonia given.
Table 4 Risk factors for acquisition of vancomycin-resistant enterococcal (VRE) colonization after transplantation for 120 liver transplant recipients.

Table 4 Risk factors for acquisition of vancomycin-resistant enterococcal (VRE) colonization after transplantation for 120 liver transplant recipients.
Table 5 Characteristics of 12 patients who had 1 test of stool samples that yielded positive results in the prospective clinical assessment for investigation.

Table 5 Characteristics of 12 patients who had 1 test of stool samples that yielded positive results in the prospective clinical assessment for investigation.
Table 3 Titers of antibody to hepatitis B surface antigen (anti-HBs) 2–4 weeks after the first vaccination From: Response to Hepatitis B Vaccine in HIV-1–Positive.

Table 3 Titers of antibody to hepatitis B surface antigen (anti-HBs) 2–4 weeks after the first vaccination From: Response to Hepatitis B Vaccine in HIV-1–Positive.
Table 6 The results of virus isolation tests before and after oseltamivir therapy. From: A Comparison of the Effectiveness of Oseltamivir for the Treatment.

Table 6 The results of virus isolation tests before and after oseltamivir therapy. From: A Comparison of the Effectiveness of Oseltamivir for the Treatment.
Figure 1 Inclusion criteria, exclusion criteria, and criteria for virologic failure. CDC, Centers for Disease Control and Prevention; ddC, zalcitabine;

Figure 1 Inclusion criteria, exclusion criteria, and criteria for virologic failure. CDC, Centers for Disease Control and Prevention; ddC, zalcitabine;
Table 1 Organisms for which rapid identification criteria are included. From: Rapid Identification of Bacteria and Yeast: Summary of a National Committee.

Table 1 Organisms for which rapid identification criteria are included. From: Rapid Identification of Bacteria and Yeast: Summary of a National Committee.
Table 1 Groups of subjects in a study of the association between antibiotic use and colonization with resistant pneumococci. From: Measuring and Interpreting.

Table 1 Groups of subjects in a study of the association between antibiotic use and colonization with resistant pneumococci. From: Measuring and Interpreting.
Table 1 Characteristics of patients at enrollment who received artesunate-amodiaquine (ASAQ) or artemether-lumefantrine (AL) for treatment of malaria.

Table 1 Characteristics of patients at enrollment who received artesunate-amodiaquine (ASAQ) or artemether-lumefantrine (AL) for treatment of malaria.
Figure 1 Principle coordinates analysis plot for 127 Escherichia coli isolates from the SENTRY and Meropenem Yearly Susceptibility Test Information Collection.

Figure 1 Principle coordinates analysis plot for 127 Escherichia coli isolates from the SENTRY and Meropenem Yearly Susceptibility Test Information Collection.
Table 1 Characteristics of the 968 Women in the Study Group

Table 1 Characteristics of the 968 Women in the Study Group
Table 3 Identification of Lactobacillus species isolated from blood cultures from Helsinki University Central Hospital, 1990–2000, and stored isolates.

Table 3 Identification of Lactobacillus species isolated from blood cultures from Helsinki University Central Hospital, 1990–2000, and stored isolates.
Table 1 Demographic and clinical characteristics of 758 admitted patients for whom cultures of nares were performed to assess methicillin-resistant Staphylococcus.

Table 1 Demographic and clinical characteristics of 758 admitted patients for whom cultures of nares were performed to assess methicillin-resistant Staphylococcus.
Table 1 Specificity of IgM immunoblot assay of sera collected during the winter and early spring months from volunteers without clinical evidence of Lyme.

Table 1 Specificity of IgM immunoblot assay of sera collected during the winter and early spring months from volunteers without clinical evidence of Lyme.
Table 1 Characteristics of study patients in survey of HIV infection in India. From: Natural History of Human Immunodeficiency Virus Disease in Southern.

Table 1 Characteristics of study patients in survey of HIV infection in India. From: Natural History of Human Immunodeficiency Virus Disease in Southern.
Table 3. Predictors of Nevirapine Reactions at Antiretroviral Therapy Initiation From: Strategies for Nevirapine Initiation in HIV-Infected Children Taking.

Table 3. Predictors of Nevirapine Reactions at Antiretroviral Therapy Initiation From: Strategies for Nevirapine Initiation in HIV-Infected Children Taking.
Table 4 Comparison of frequencies of Legionella pneumophila serogroup 1 urinary antigen results and antibody titer results among patients with Pontiac.

Table 4 Comparison of frequencies of Legionella pneumophila serogroup 1 urinary antigen results and antibody titer results among patients with Pontiac.
Figure 1. Algorithm for classifying patients with hospital-acquired pneumonia according to the Consensus Statement of the American Thoracic Society. Adapted.

Figure 1. Algorithm for classifying patients with hospital-acquired pneumonia according to the Consensus Statement of the American Thoracic Society. Adapted.
From: Rotarix: A Rotavirus Vaccine for the World

From: Rotarix: A Rotavirus Vaccine for the World
Figure 4 Monthly all-cause (A-C) and pneumonia and influenza (P&I) mortality rates among Japanese children aged 5–9 years. Vertical dotted lines, January.

Figure 4 Monthly all-cause (A-C) and pneumonia and influenza (P&I) mortality rates among Japanese children aged 5–9 years. Vertical dotted lines, January.

Similar presentations

Ads by Google